Sanara Medtech Inc. (SMTI) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Sanara Medtech Inc. is a medical technology company focused on surgical solutions, specifically soft tissue repair and bone fusion products. Following the discontinuation of its Tissue Health Plus (THP) segment in September 2025, the Company now operates as a single reportable segment (Sanara Surgical). The THP segment is reported as discontinued operations.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Revenue | $27.80 million | $23.43 million |
| Gross Profit | $25.87 million | $21.60 million |
| Gross Margin | 93.1% | 92.2% |
| Operating Income | $2.65 million | $0.83 million |
| Net Income (Continuing Ops) | $0.40 million | ($0.62 million) Loss |
| Net Income (Total) | $0.46 million | ($3.53 million) Loss |
| Adjusted EBITDA | $4.26 million | $2.70 million |
| Cash and Equivalents | $13.59 million | $20.69 million |
| Long-Term Debt | $46.23 million | $45.97 million |
| Operating Cash Flow | ($2.47 million) Used | ($2.00 million) Used |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 19% year-over-year, driven primarily by a 21% increase in soft tissue repair product sales (led by CellerateRX Surgical and BIASURGE), offset by a slight 2% decline in bone fusion products.
- Profitability: The Company returned to profitability in continuing operations, reporting net income of $0.40 million compared to a net loss of $0.62 million in Q1 2025. This turnaround was driven by revenue growth and reduced R&D expenses, despite higher SG&A and interest costs.
- Discontinued Operations: Q1 2025 included a significant loss of $2.91 million from the THP segment due to asset impairments and winding down costs. Q1 2026 reported a net income of $0.06 million from discontinued operations, reflecting minimal remaining costs.
- Expense Trends: SG&A expenses increased by $2.75 million (14.4%) due to higher sales commissions and marketing spend. R&D expenses decreased by $0.19 million due to the timing of product enhancement initiatives.
- Debt Service: Interest expense increased to $1.80 million from $1.32 million due to a larger outstanding principal balance on the CRG Term Loan. The Company elected to pay all interest in cash during Q1 2026, whereas Q1 2025 included paid-in-kind interest.
Guidance, Outlook, and Risks
- Strategic Shift: Management has fully exited the value-based wound care (THP) strategy to focus exclusively on the surgical market. The Company is dissolving the Sanara Collagen Peptides (SCP) subsidiary and terminated the Tufts University license agreement effective April 2026.
- Liquidity: Management believes current cash on hand ($13.6 million) combined with expected cash flows will fund operations for at least the next 12 months. Cash burn from winding down THP is expected to be minimal for the remainder of 2026.
- Debt Covenants: The Company is in compliance with all covenants under the CRG Term Loan. Key covenants include maintaining liquidity above $3.0 million and meeting annual minimum revenue targets (e.g., $85.0 million for the 12 months ending Dec 31, 2026).
- Investments: The Company holds equity method investments in BMI (12.14%), ChemoMouthpiece (6.59%), and SI Technologies (50%). Share of losses from these investments totaled $0.46 million in Q1 2026.
- Risks: Key risks include the ability to meet future capital requirements, compliance with debt obligations, and the commercial success of new product launches (e.g., BMI OsStic). The Company also faces risks related to the failure of third-party assessments and regulatory approvals.
Investor Verification Checklist
- Debt Covenant Compliance: Verify the Company's ability to meet the $85 million annual revenue covenant for the fiscal year ending December 31, 2026, given the current quarterly run rate.
- Cash Burn Rate: Monitor the trend in operating cash flow usage, which increased to $2.47 million in Q1 2026, to ensure the 12-month liquidity runway remains valid.
- THP Wind-Down Costs: Confirm that no material unexpected costs arise from the final dissolution of the THP segment and related legal/contractual obligations.
- Equity Method Investments: Review the financial health of BMI and ChemoMouthpiece, as their losses directly impact Sanara's net income and there is a risk of impairment if milestones are not met.
- Related Party Transactions: Review ongoing royalty payments and consulting fees to Rochal Industries and other related parties to ensure terms remain at arm's length.